Establishment of bladder cancer spheroids and cultured in microfluidic platform for predicting drug response

IF 6.1 2区 医学 Q1 ENGINEERING, BIOMEDICAL Bioengineering & Translational Medicine Pub Date : 2023-12-04 DOI:10.1002/btm2.10624
Qiao Xiong, Ting Liu, Yidie Ying, Xiaowen Yu, Ziwei Wang, Hongliang Gao, Tianhai Lin, Weihua Fan, Zhensheng Zhang, Qiang Wei, Yuqing Ge, Shuxiong Zeng, Chuanliang Xu
{"title":"Establishment of bladder cancer spheroids and cultured in microfluidic platform for predicting drug response","authors":"Qiao Xiong,&nbsp;Ting Liu,&nbsp;Yidie Ying,&nbsp;Xiaowen Yu,&nbsp;Ziwei Wang,&nbsp;Hongliang Gao,&nbsp;Tianhai Lin,&nbsp;Weihua Fan,&nbsp;Zhensheng Zhang,&nbsp;Qiang Wei,&nbsp;Yuqing Ge,&nbsp;Shuxiong Zeng,&nbsp;Chuanliang Xu","doi":"10.1002/btm2.10624","DOIUrl":null,"url":null,"abstract":"<p>Cisplatin-containing combination chemotherapy has been used as the standard treatment for bladder cancer patients at advanced stage. However, nearly 50% of patients are nonresponders. To guide the selection of more effective chemotherapeutic agents, a bladder cancer spheroids microfluidic drug sensitivity analysis system was established in this study. Bladder cancer spheroids were established and successfully cultured in a customized microfluidic device to assess their response to different chemotherapeutic agents. The in vitro drug sensitivity results were also compared to patient-derived xenograft (PDX) models and clinical responses of patients. As a result, bladder cancer spheroids faithfully recapitulate the histopathological and genetic features of their corresponding parental tumors. Furthermore, the in vitro drug sensitivity outcomes of spheroids (<i>n</i> = 8) demonstrated a high level of correlation with the PDX (<i>n</i> = 2) and clinical response in patients (<i>n</i> = 2). Our study highlights the potential of combining bladder cancer spheroids and microfluidic devices as an efficient and accurate platform for personalized selection of chemotherapeutic agents.</p>","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":null,"pages":null},"PeriodicalIF":6.1000,"publicationDate":"2023-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/btm2.10624","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioengineering & Translational Medicine","FirstCategoryId":"5","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/btm2.10624","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0

Abstract

Cisplatin-containing combination chemotherapy has been used as the standard treatment for bladder cancer patients at advanced stage. However, nearly 50% of patients are nonresponders. To guide the selection of more effective chemotherapeutic agents, a bladder cancer spheroids microfluidic drug sensitivity analysis system was established in this study. Bladder cancer spheroids were established and successfully cultured in a customized microfluidic device to assess their response to different chemotherapeutic agents. The in vitro drug sensitivity results were also compared to patient-derived xenograft (PDX) models and clinical responses of patients. As a result, bladder cancer spheroids faithfully recapitulate the histopathological and genetic features of their corresponding parental tumors. Furthermore, the in vitro drug sensitivity outcomes of spheroids (n = 8) demonstrated a high level of correlation with the PDX (n = 2) and clinical response in patients (n = 2). Our study highlights the potential of combining bladder cancer spheroids and microfluidic devices as an efficient and accurate platform for personalized selection of chemotherapeutic agents.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
建立膀胱癌球体并在微流控平台中培养,以预测药物反应
含顺铂联合化疗已成为晚期膀胱癌患者的标准治疗方案。然而,近50%的患者无反应。为了指导更有效的化疗药物的选择,本研究建立了膀胱癌球体微流控药物敏感性分析系统。在定制的微流体装置中建立并成功培养膀胱癌球体,以评估其对不同化疗药物的反应。体外药敏结果也与患者来源的异种移植(PDX)模型和患者的临床反应进行了比较。因此,膀胱癌球状体忠实地概括了其相应亲代肿瘤的组织病理和遗传特征。此外,球体的体外药敏结果(n = 8)与患者的PDX (n = 2)和临床反应(n = 2)高度相关。我们的研究强调了将膀胱癌球体和微流控装置结合起来作为个性化选择化疗药物的有效和准确平台的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Bioengineering & Translational Medicine
Bioengineering & Translational Medicine Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
8.40
自引率
4.10%
发文量
150
审稿时长
12 weeks
期刊介绍: Bioengineering & Translational Medicine, an official, peer-reviewed online open-access journal of the American Institute of Chemical Engineers (AIChE) and the Society for Biological Engineering (SBE), focuses on how chemical and biological engineering approaches drive innovative technologies and solutions that impact clinical practice and commercial healthcare products.
期刊最新文献
Fecal microbiota transplantation for the treatment of intestinal and extra‐intestinal diseases: Mechanism basis, clinical application, and potential prospect ColMA‐based bioprinted 3D scaffold allowed to study tenogenic events in human tendon stem cells Facile minocycline deployment in gingiva using a dissolvable microneedle patch for the adjunctive treatment of periodontal disease Temperature‐sensitive sodium beta‐glycerophosphate/chitosan hydrogel loaded with all‐trans retinoic acid regulates Pin1 to inhibit the formation of spinal cord injury‐induced rat glial scar Recent regulatory developments in EU Medical Device Regulation and their impact on biomaterials translation
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1